Objectives: To evaluate the impact of obesity and morbid obesity on short-term outcomes after laparoscopic adrenalectomy. Methods: The study included 520 consecutive patients undergoing laparoscopic adrenalectomy for adrenal tumor. The entire study group was divided depending on the body mass index: group 1 (normal weight), <25 kg/m . Additionally, group 4 (morbidly obese) was distinguished. Study end-points were: operative time, intraoperative blood loss, total length of hospital stay, morbidity rate and 30-day readmission rate. Results: The mean operative times were 88.8, 94.7, 93.5, and 99.9 min in groups 1, 2, 3 and 4, respectively (P = 0.1444). Complications were comparable between groups (12.8% vs 8.8% vs 8.2% vs 11.5%, P = 0.5295). The mean intraoperative blood loss was 66.8 versus 78.3 versus 60.7 versus 92.4, P = 0.1399. There were no differences in conversion rate between groups. Conclusions: Obesity has no influence on short-term outcomes of laparoscopic transperitoneal adrenalectomy. This procedure is feasible regardless of the body mass index. Therefore, it can be offered to all patient groups including those morbidly obese individuals in whose case preoperative weight loss seems unnecessary.
Introduction
The rapid development of modern imaging technologies has led to an increase in the number of incidentally discovered adrenal tumors. 1, 2 In fact, in 1994 this intriguing phenomenon was provocatively described by Griffing as a new endocrine epidemic of AIDS: Adrenal Incidentaloma Discovered Serendipitously. 3 However, it is obesity that has been recognized, to be the major epidemic of the 21st century, together with cancer diseases. 4 These two facts are of great importance for contemporary surgeons. First, over the past 20 years, minimally invasive adrenalectomy has practically replaced open surgery and become the gold standard in the treatment of benign as well as most malignant adrenal tumors. 5, 6 At the same time, laparoscopic bariatric surgery has become the gold standard for the treatment of morbid obesity. [7] [8] [9] Second, numerous studies in other fields of surgery have shown that apart from the obvious implications, such as related comorbidities, obesity negatively impacts surgical outcomes. 10, 11 Finally, although the link between obesity and adrenal pathology has been suggested, but not confirmed in larger studies, a significant proportion of patients suffer from both morbid obesity and adrenal pathology. 12 Although there are studies documenting the feasibility and safety of minimally invasive adrenalectomy in obese patients, the data are inconsistent. 13, 14 The aim of the present study was to evaluate the impact of obesity and morbid obesity on short-term outcomes after laparoscopic transperitoneal adrenalectomy.
Methods
The study included consecutive patients undergoing laparoscopic transperitoneal adrenalectomy for adrenal tumor at the 2nd Department of General Surgery, Jagiellonian University Medical College, Krak ow, Poland, between June 2006 and November 2015. In this tertiary referral university medical unit, we focus mainly on laparoscopic surgery (primarily of colorectal, gastric, bariatric, pancreatic and hepatobiliary types). Every year more than 700 advanced laparoscopic procedures are carried out, and the annual volume of adrenalectomy is 50-60 cases.
Patients who were submitted to open surgery or patients with an inoperable tumor with distant metastases were excluded from the study. Preoperative staging in all cases was comprised of computed tomography and/or magnetic resonance imaging, or positron emission tomography scan in selected cases. Before surgery, a routine panel of laboratory tests was carried out to establish the hormonal activity of the tumor. The evaluation included plasma cortisol, urinary free cortisol, adrenocorticotropic hormone, dexamethasone suppression test, dehydroepiandrosterone sulfate, 17-hydroxyprogesterone, testosterone, aldosterone, urinary aldosterone, plasma renin activity, metoxycatecholamines and vanillylmandelic acid excretion. In the case of suspected pheochromocytoma, patients were preoperatively treated with alphablockers, additional beta-blockers in the case of co-existing tachycardia, and intravenous volume expansion with crystalloids and colloids (2000 mL/day starting on the day before surgery).
The operative method of choice in our department is laparoscopic transperitoneal lateral total adrenalectomy, which is carried out similarly to described elsewhere. 15 In cases of bilateral disease, two-staged adrenalectomy was carried out. The policy of our unit is to always begin with laparoscopy (also in cases of highly suspected cancer), and convert when safe and radical dissection is impossible. During the study period, there was only one patient with a 24-cm tumor, who was initially submitted to open adrenalectomy. In all remaining cases, we attempted the laparoscopic procedure. Every procedure was carried out by a team of experienced laparoscopic surgeons (at least one endocrine laparoscopic surgeon with a minimum of 50 adrenalectomies carried out).
For the purpose of further analysis, the entire study group was divided depending on their BMI: group 1 (normal weight), BMI <25 kg/m 2 ; group 2 (overweight), BMI 25 to <30 kg/m 2 ; group 3 (obese), BMI 30 to <35 kg/m 2 and BMI 35 to <40 kg/m 2 without obesity-related comorbidities. Additionally, group 4 (morbidly obese) was distinguished and comprised patients who, according to Interdisciplinary European Guidelines on Metabolic and Bariatric Surgery, were candidates for bariatric surgical treatment of obesity. 16 Therefore, this group included patients with BMI ≥40 kg/m 2 or BMI 35-40 kg/m 2 with obesity-related comorbidities. Study end-points were: operative time, intraoperative blood loss, total length of hospital stay, morbidity rate (according to Clavien-Dindo classification) and 30-day readmission rate.
All procedures were approved by the local Ethics Review Committee (KBET 45/B/2010), and carried out in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. Informed consent for proposed surgical treatment was obtained from all patients before surgery. As the study did not include animals, an animal approved project number was not required.
All data were analyzed with Statistica v.10 (StatSoft, Tulsa, OK, USA). The results are presented as mean AE SD, or median and IQR when appropriate. The study of categorical variables used the v 2 -test of independence. The ShapiroWilk test was used to check for normal distribution of data. In the case of non-normally distributed quantitative variables, groups were compared using the Kruskal-Wallis test. Results were considered statistically significant when the P-value was found to be <0.05.
Results
During the study period, 520 patients with adrenal pathology were treated. There were no differences between groups regarding age, location, and size of the tumor (left/right) and its characteristics (benign/malignant, functioning/non-functioning). However, patients from groups 2-4 were on average 9 years older than patients in group 1. They also had more comorbidities and higher ASA grades. The rate of patients with previous abdominal surgeries increased with BMI. There were also differences between groups in the hormonal status of removed tumors. There were significantly more Cushing's syndrome patients in the higher BMI groups. However, the size and character (benign/malignant) of the lesion were not different. Table 1 details baseline characteristics of the study groups. Table 2 shows perioperative outcomes in study groups. The mean operative time was 88.8, 94.7, 93.5, and 99.9 min in groups 1, 2, 3 and 4, respectively (P = 0.1444). The mean intraoperative blood loss was comparable between groups (66.8 AE 122.2 vs 78.3 AE 131.7 vs 60.7 AE 95.3 vs 92.4 AE 144.9, P = 0.1399). Altogether, conversion was necessary in seven patients: three cases in group 1, two cases in group 3, and one case each in groups 3 and 4 (P = 0.6524). The reasons for conversion were: hemodynamic instability and abnormal location of the tumor, infiltration to adjacent organs, infiltration of the abdominal wall, damage of the tumor capsule, adhesions after previous surgery (92), and uncontrolled bleeding.
The overall complication rate in the entire study group was 10.2%. Detailed complications are presented in Table 3 . We did not show differences in the rate and the severity of complications between groups (12.8% vs 8.8% vs 8.2% vs 11.5%, P = 0.5295). A single mortality was reported in group 1 -a patient with pheochromocytoma (ASA grade 4) died 7 days after surgery as a result of cardiopulmonary failure. The median length of hospital stay was 3 days irrespective of the group. Readmission within 30 days post-surgery was necessary in seven cases: one case in group 1, four cases in group 2, one case in group 3 and one case in group 4 (P = 0.5547). The reasons for readmission included: deep surgical site infection (93), pneumonia (92) and intraabdominal abscess (92). Table 2 summarizes postoperative outcomes in study groups.
Discussion
In the present study comprising more than 500 patients undergoing transabdominal lateral adrenalectomy, we did not find significant differences in short-term outcomes between not obese, overweight, obese and morbidly obese patients. Despite existing differences in baseline demographic characteristics and general physical status between groups, these factors had no further influence on clinical outcomes, such as operative time, blood loss, conversion and complication rate, length of hospital stay, and readmissions. The main purpose of the present study was to answer the question of whether laparoscopic transabdominal adrenalectomy can be safely offered to patients with morbid obesity who are potential candidates for surgical treatment. It is a relatively common clinical problem we encounter in our everyday practice. As most adrenal tumors are benign adenomas with typical appearance in imaging studies and either no or only subclinical hormonal activity, the delay in surgery (6-12 months) in such cases does not necessarily lead to worse outcomes and seems possible to accept if significant weight loss would be required, especially as this approach has been proposed in other fields of surgery, including surgery for the early stage of malignancy. 17, 18 Obviously, this does not apply to Cushing's syndrome and pheochromocytomas in which adrenalectomy as a first step procedure is beyond doubt. The present study shows, however, that this approach seems to be unnecessary as a result of comparable outcomes regardless of BMI. Furthermore, even in the morbidly obese group (consisting of potential future candidates for bariatric surgery), no increase in adverse events was observed.
The reported complication rate in our group was 10.2%, in line with previous studies. 13, 19, 20 The data on the relationship between complications and body mass index are contradictory. Dancea et al. concluded that although BMI is associated with an increased complication rate, it should not preclude elective laparoscopic adrenalectomy.
14 This was confirmed by Economopoulos et al. in a study comprising 365 cases -obesity should not be used to discourage experienced adrenal surgeons from carrying out laparoscopic adrenalectomy through the transperitoneal approach. 21 Interestingly, having analyzed more than 1600 patients, Kazaure et al. noticed that obesity is an independent risk factor that needs to be considered in surgical decisions regarding adrenalectomy, because morbidly obese adrenalectomy patients are particularly at risk for wound and septic complications. 13 In our opinion, the discrepancy in results comes from the relatively high rate of open procedures in this group. Almost 20% of patients were operated from an open approach, and both univariate and multivariate analysis showed that it was an even stronger risk factor for infectious complications. In our study group, which practically consisted of only laparoscopic cases, a higher BMI was not associated with an increase in the complication rate.
The operative time (shorter than 100 min irrespectively of the BMI) measured from the first trocar placement to the last skin stitch was shorter than in other studies. 5, 22, 23 Also, the conversion rate was similar to the results reported by other authors. 24 According to the present results, morbid obesity was not associated with prolonged operative time and increased intraoperative blood loss, and did not influence postoperative outcomes compared with not obese patients. Therefore, we conclude that bariatric surgery is not necessary as the first step of surgical treatment, although it can be obviously offered later to morbidly obese individuals fulfilling criteria for weight loss surgery.
Another issue to consider is the intraoperative route of access to the adrenal glands. No doubt minimally invasive surgery is preferred in the treatment of most tumors. There are authors who prefer retroperitoneal access in the case of smaller tumors. 25 Recent meta-analyses showed no statistical differences between laparoscopic and retroperitoneoscopic access regarding perioperative outcomes; however, postoperative recovery was slightly faster in the latter. 24, 26 For instance, Zon ca et al. suggested that retroperitoneoscopic access can also be used safely in morbidly obese patients, and indeed might be associated with more favorable postoperative course, shorter hospital stay, better cosmetic outcome and quicker recovery. 27 In his opinion, it might also be more convenient in cases of bilateral adrenal tumors. In our center, laparoscopic transperitoneal lateral approach is the preferred access to adrenal pathology. As most incidentalomas >4 cm are removed for oncological reasons, careful inspection of the abdominal cavity is of great importance in these cases. 28 Especially as laparoscopic approach is no worse than retroperitoneal, and can also be carried out in patients after previous abdominal surgeries. 29, 30 Hence, in all of these cases, we suspect a malignant process to some extent. In addition, all our patients with bilateral adrenal pathology undergo a two-staged procedure, so changing position is not an issue. In light of the current literature and our observations, we conclude that the choice of access (laparoscopic/ retroperitoneoscopic) should be based on the experience and preference of the surgeon rather than on the characteristics of the patient and his/her bodyweight.
The present study had some limitations that are typical for single-center retrospective studies. Furthermore, we analyzed only the outcomes of an adrenalectomy excluding the cumulative results of adrenal and bariatric surgery. To fully answer the question as to which surgery should first be offered to a patient with morbid obesity and adrenal tumor requiring surgical treatment, a prospective randomized study comparing two approaches (bariatric surgery following adrenal surgery, or adrenal surgery after bariatric surgery) would be of great use. As a referral high-volume center, we have a team of surgeons with extensive expertise in laparoscopic adrenal surgery, which might influence the outcomes as well. 6 Therefore, the present results should be interpreted as an experience of the entire minimally invasive endocrine center rather than of a single surgeon. Last, but not least, we did not analyze other approaches to adrenal pathology, as well as modifications of widely established techniques. We conclude that obesity has no influence on short-term outcomes after laparoscopic transperitoneal adrenalectomy. It is feasible regardless of the body mass index. Therefore, it can be offered to all patient groups, including morbidly obese individuals for whom preoperative weight loss seems unnecessary.
